TrialCancer chemotherapy and pharmacology2021

A Phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX02 to reference CN- and EU-sourced trastuzumab in healthy subjects.

X Zhu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.